Core Insights - Emerald Wealth Partners' Focused Equity Strategy achieved a return of +13.8% (gross) and 13.2% (net) in 2025, with a 2.2% gain in Q4 [1] - The market experienced its third consecutive year of positive returns in 2025, driven by significant capital investments in AI infrastructure [1] - Macroeconomic surveys indicate the best outlook in five years, fueled by expectations of lower US Federal Reserve interest rates and increased investment in AI [1] Company Highlights - Microsoft Corporation (NASDAQ:MSFT) was the largest holding in the Focused Equity Strategy and contributed +1.1% to the overall performance in 2025, with its stock up 15.6% [3] - As of March 12, 2026, Microsoft stock closed at $401.86 per share, with a one-month return of 0.13% and a 52-week gain of 3.42% [2] - Microsoft has a market capitalization of $2.987 trillion, indicating its significant position in the market [2] Investment Sentiment - Truist raised the price target for Microsoft to $675 and reiterated a buy recommendation, reflecting strong confidence in the stock [4] - Microsoft ranks second among the 40 Most Popular Stocks Among Hedge Funds, with 312 hedge fund portfolios holding the stock at the end of Q4, unchanged from the previous quarter [4] - While Microsoft is recognized for its potential, there is a belief that certain AI stocks may offer greater upside potential with less downside risk [4]

Core Viewpoint - Advanced Biomed Inc. announced a reverse stock split at a ratio of 1 for 20 shares, effective February 20, 2026, to comply with Nasdaq Listing Rule 5550(a)(2) [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split was approved by a majority of the voting power on January 12, 2026, with the board finalizing the ratio on January 30, 2026 [2]. - The objective of the reverse split is to enable the company to meet the minimum bid price requirement of $1.00 per share on Nasdaq [3]. - Following the reverse split, the total issued and outstanding common shares will decrease from 27,290,710 to approximately 1,364,536 shares [6]. Group 2: Shareholder Impact - Each 20 shares will convert into one share, maintaining the par value of US$0.001, and will not alter stockholders' percentage ownership, except for minor changes due to fractional shares [4]. - No fractional shares will be issued; stockholders will receive one full share instead of any fractional share resulting from the split [5]. Group 3: Company Overview - Advanced Biomed Inc. is a biotechnology company focused on innovative biomedical products for precision medicine and advanced diagnostics [1][7]. - The company operates through a subsidiary in Taiwan and has developed a proprietary microfluidic platform for advanced circulating tumor cell detection and analysis [8].

Group 1 - Microsoft Corporation (NASDAQ:MSFT) is the top stock pick for billionaire Chase Coleman III, accounting for a 10.49% share valued at $3.40 billion in his portfolio [1] - Citi reported that software stocks, including Microsoft, have experienced a decline of at least 10% in the past month, with terminal multiples now below forward P/E ratios, despite higher consensus EPS estimates for 2025-2027 [2] - Melius Research downgraded Microsoft from 'Buy' to 'Hold' with a price target of $430, citing the need for increased AI-driven capital expenditures to compete with Google and Amazon, which may strain free cash flow [3] Group 2 - Microsoft develops software, cloud services, devices, and enterprise solutions across various segments, including Productivity and Business Processes, Intelligent Cloud, and More Personal Computing [5] - There are opinions suggesting that while Microsoft is a potential investment, certain AI stocks may offer greater upside potential and carry less downside risk [6]

Market Overview - US equities showed strong momentum in 2025, achieving double-digit gains for the second consecutive year, with a rapid recovery from a bear market dip in April [1] - Market leadership has narrowed, with Mega-cap stocks and AI-driven companies dominating the landscape [1] Mar Vista U.S. Quality Strategy Performance - The Mar Vista U.S. Quality strategy reported a net-of-fees gain of +0.20% in Q4 2025, compared to the Russell 1000® Index's +2.41% and the S&P 500® Index's +2.65% [1] - Favorable stock selection in communication services, consumer discretionary, and financials contributed positively to performance, while information technology, materials, and healthcare detracted from it [1] Economic Outlook - In 2026, markets will need to balance strong fundamentals with increasing economic uncertainties [1] Microsoft Corporation Analysis - Microsoft Corporation (NASDAQ:MSFT) had a one-month return of -1.14% and a 52-week gain of 10.41%, closing at $470.67 per share on January 13, 2026, with a market capitalization of $3.499 trillion [2] - The stock faced pressure in Q4 2025 due to concerns over rising costs for AI data infrastructure, with capital expenditures expected to increase in 2026 [3] - Microsoft is well-positioned to fund its growth through a large base of operating cash flows, despite having meaningful exposure to OpenAI, which remains relatively unproven [3]

Core Viewpoint - Microsoft Corporation (NASDAQ:MSFT) is recognized as a leading software infrastructure stock by hedge funds, with recent price target adjustments reflecting ongoing confidence in its growth potential driven by AI integration [1][3]. Group 1: Analyst Ratings and Price Targets - Wells Fargo has reduced its price target for Microsoft from $700 to $665 while maintaining an Outperform rating, indicating a positive outlook despite the adjustment [1]. - Jefferies analyst Brent Thill reiterated a Buy rating with a price target of $675, emphasizing Microsoft's AI integration as a significant growth driver [3]. Group 2: AI Landscape and Market Trends - Wells Fargo's software-sector update for 2026 highlights AI as a critical focus area, suggesting that investors can find opportunities in infrastructure providers, established companies, and innovation-driven platforms [2]. - The firm anticipates variability in AI adoption trends but believes that fundamental drivers will support performance through 2026 [2]. Group 3: Company Overview - Microsoft develops and sells a diverse range of software, cloud services, devices, and business solutions, catering to both individual users and enterprise customers globally [4].

Group 1 - Advanced Biomed Inc. has entered into an agreement to sell 100% of its Hong Kong subsidiary for a total purchase price of US$23,000 based on a valuation report [1] - The transaction includes the transfer of all intellectual property owned by the Hong Kong subsidiary, including that of its wholly owned subsidiary, Shanghai Sglcell Biotech Co., Ltd. [2] - The CEO of Advanced Biomed stated that the divestment is part of a strategic realignment to centralize clinical trials in Taiwan due to evolving regulatory requirements in China [3] Group 2 - The company operates through its Taiwan subsidiary, which has developed a proprietary microfluidic platform for advanced circulating tumor cell detection and analysis [4] - The product portfolio includes devices and biochips designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for global expansion [4]

Core Insights - Harbor Capital Appreciation Fund reported a return of 5.11% in Q3 2025, underperforming compared to the Russell 1000® Growth Index at 10.51% and the S&P 500 Index at 8.12% [1] - The fund primarily invests in U.S. companies with a market capitalization of at least $1 billion, focusing on equity securities [1] Fund Performance - U.S. equities showed strong performance in Q3 2025, driven by AI momentum and robust corporate earnings, with support from the Federal Reserve's interest rate cut [1] - The fund's top five holdings were highlighted as key investment picks for 2025 [1] Microsoft Corporation (NASDAQ:MSFT) - Microsoft Corporation's stock gained 11.08% over the last 52 weeks, closing at $488.02 per share with a market capitalization of $3.628 trillion on December 24, 2025 [2] - Concerns regarding Microsoft's relationship with OpenAI, particularly after the Oracle/OpenAI deal announcement, led to underperformance of its shares [3] - The fund's underweight position in Microsoft relative to the index positively contributed to its relative returns [3] - Microsoft reported revenue of $77.7 billion in Q1 FY 2026, reflecting an 18% increase, or 17% when adjusted for constant currency [3] - The fund suggests that certain AI stocks may offer greater upside potential and less downside risk compared to Microsoft [3]

Core Insights - November is traditionally a strong month for the stock market, and the artificial intelligence (AI) sector is projected to grow rapidly, reaching a market size of US$1.68 trillion by 2031, with a CAGR of 36.89% from this year [1] Group 1: AI Sector Growth - The AI sector is experiencing significant growth, making it a focal point for investors looking for opportunities in AI-driven stocks [1] - Companies like QUALCOMM, Microsoft, and Meta Platforms are highlighted as momentum picks for November, benefiting from the sector's growth [2][9] Group 2: Driehaus Investment Strategy - The Driehaus strategy, known as "buy high and sell higher," emphasizes investing in stocks that are increasing in price rather than those in decline [3] - Key criteria for this strategy include strong earnings growth rates, impressive earnings projections, and a history of beating estimates [5] Group 3: Screening Parameters - Stocks are screened based on Zacks Rank (1-3) and Momentum Score (A or B), which have shown to provide the best upside potential [6][7] - Specific parameters include last 5-year average EPS growth rates above 2%, trailing 12-month EPS growth greater than 0, and positive percentage change in the 50-day moving average [8][10] Group 4: Selected Stocks - QUALCOMM (QCOM) has a Zacks Rank of 3 and a Momentum Score of A, with an average trailing four-quarter earnings surprise of 6.2% [10] - Microsoft (MSFT) holds a Zacks Rank of 3 and a Momentum Score of B, with an average trailing four-quarter earnings surprise of 8.5% [11] - Meta Platforms (META) has a Zacks Rank of 2 and a Momentum Score of B, with an average trailing four-quarter earnings surprise of 18.9% [12]

Core Insights - Wedgewood Partners' third-quarter 2025 investor letter indicates that AI stocks continue to dominate Wall Street's interest, with the Wedgewood Composite achieving a net return of 5.9%, underperforming compared to the S&P's 8.1% and the Russell 1000 Growth Index's 10.5% [1] Company Summary: Microsoft Corporation (NASDAQ:MSFT) - Microsoft Corporation reported a one-month return of 1.47% and a 52-week gain of 21.92%, with its stock closing at $517.66 on October 21, 2025, and a market capitalization of $3.848 trillion [2] - The company has invested heavily in capital expenditures, adding over 2 gigawatts of data center capacity in the past year, resulting in gross property, plant, and equipment, and capitalized leases reaching nearly $370 billion, an increase of $260 billion since fiscal 2020 [3] - Gross cash flow has risen from $60 billion in 2020 to over $140 billion in 2025, indicating a consistent return on capital in the high 20s, which is considered an attractive return given the scale of investment [3] Market Position - Microsoft ranks second among the 30 Most Popular Stocks Among Hedge Funds, with 294 hedge fund portfolios holding its stock at the end of Q2 2025, up from 284 in the previous quarter [4] - In Q4 of fiscal year 2025, Microsoft reported revenue of $76.4 billion, marking an 18% increase, or 17% when adjusted for constant currency [4]

Core Insights - LeMaitre Vascular, Inc. will release its Q3 2025 financial results on November 6, 2025, after market close [1] - A conference call is scheduled for the same day at 5:00 PM EST to discuss the results and company outlook [1] Company Overview - LeMaitre Vascular is a provider of devices, implants, and services for treating peripheral vascular disease, which affects over 200 million people globally [3] - The company develops, manufactures, and markets disposable and implantable vascular devices aimed at vascular surgeons [3]